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Hepatitis C virus (HCV), especially the genotype 1, is naturally resistant to the antiviral effects of interferon-alpha (IFN-).
Expression of the whole HCV genome and the NS5A protein has been suggested to interfere with the antiviral activity of
IFN-. Here we have analyzed the effect of individual or various combinations of HCV proteins on IFN--mediated antiviral
effect against vesicular stomatitis virus (VSV). When the structural proteins (core-E1-E2) of HCV genotype 1 were expressed
in human osteosarcoma cells in a tetracycline-regulated manner, partial VSV resistance to IFN- was established. This was
seen as an enhancement of both viral protein synthesis and production of infectious virus. Priming of core-E1-E2-expressing
cells with low doses of IFN- (10 IU/ml) partially restored the antiviral activity of IFN-. The core (high-level expression) and
NS4B protein expression also showed some rescue of VSV replication. In this model cell system NS3A–NS4A complex and
NS5A showed no inhibition of IFN--induced antiviral activity. Our results indicate that the expression of structural proteinsevier Sci
x protINTRODUCTION
Hepatitis C virus (HCV) is a single-stranded, positive-
sense RNA virus belonging to the Flaviviridae family.
HCV genome consists of about 9.6 kb with one open
reading frame encoding for a polypeptide (about 3000
amino acids long), consisting of three structural (Core,
E1, and E2) and six nonstructural ((NS2 (protease), NS3
(protease-helicase), NS4A (cofactor for NS3), NS4B,
NS5A (serine phosphoprotein), and NS5B (RNA polymer-
ase)) proteins (Bartenschlager and Lohmann, 2000; Reed
and Rice, 2000). Approximately 3% of the world’s popu-
lation is estimated to have chronic HCV infection (Alter,
1995), which may expose the infected individuals to cir-
rhosis, chronic liver failure, and hepatocellular carci-
noma (Saito et al., 1990). The reasons for hepatitis C
becoming chronic are unclear but viral as well as host
factors are thought to be involved. Certain viral geno-
types may be more pathogenic than others but racial,
gender-specific, and genetic (e.g., HLA types) factors
may also be important (Bruno et al., 1997; Davis et al.,
1998; Hoofnagle and di Bisceglie, 1997; McHutchison et
al., 1998). Liver cells may also have poor ability to pro-
duce and respond to type I interferons (IFNs), which
could contribute to their inability to efficiently resist viral
infections (Keskinen et al., 1999; Mele´n et al., 2000).
Although IFN- combined with ribavirin have shown
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164favorable results in the treatment of chronic hepatitis C
(Davis et al., 1998; Hoofnagle and di Bisceglie, 1997;
McHutchison et al., 1998; Poynard et al., 1996), HCV
genotype 1 is naturally resistant to the antiviral actions of
IFN-. IFNs are classified into type I (IFN-, -, and -)
and type II (IFN-) IFNs and they have antiviral, antipro-
liferative, and immunomodulatory effects, which are me-
diated by the gene products of IFN-inducible genes
(Stark et al., 1998). The antiviral effects of IFNs are
mediated by at least Mx proteins, 2,5-oligoadenylate
synthetases (OAS), RNase L, and PKR (Stark et al., 1998).
IFNs also upregulate HLA class I and II expression
(Keskinen et al., 1997), which are indirectly involved in
antiviral defense. HCV has been described to have sev-
eral mechanisms to avoid IFN-mediated antiviral re-
sponse (Tan and Katze, 2001). Initially, in yeast the NS5A
protein of HCV was reported to inhibit the action of PKR,
which regulates protein synthesis through phosphoryla-
tion of the initiation factor eIF2 (Gale et al., 1998). The
other viral envelope glycoprotein, E2, also inhibited the
kinase activity of PKR and blocked its inhibitory effect on
protein synthesis and cell growth (Taylor et al., 1999). The
NS5A protein also inhibited the antiviral activity of IFN-
against ECMV and VSV infections (Gale et al., 1999;
Podevin et al., 2001; Polyak et al., 1999; Song et al., 1999)
as well as it was shown to interfere with TNF- signaling
(Park et al., 2002). Expression of the whole HCV polypro-
tein in a tetracycline-regulated system was shown to
inhibit IFN--induced Jak-STAT pathway (Heim et al.,
1999) and the antiviral actions of IFN- (Francois et al.,of HCV may impair the antiviral activity of IFNs. © 2002 Els
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2000). Some inhibition in IFN-mediated antiviral activity
was observed in cell lines expressing NS3, NS4, and
NS5 but not in those expressing core, E1, E2, NS2, or
NS3 proteins (Aizaki et al., 2000). HCV core protein has
been studied in a murine model, where core protein
expression resulted in immunosuppression, prolonged
viremia, and enhanced mortality (Large et al., 1999). HLA
class I cell-surface expression and intracellular proteo-
some activity were not affected by the HCV protein ex-
pression (Moradpour et al., 2001).
In the present work we have analyzed the effect of
HCV gene expression on IFN-mediated antiviral re-
sponse in U-2 OS human osteosarcoma cell lines ex-
pressing HCV proteins in a tetracycline-regulated man-
ner. We show that the expression of HCV core-E1-E2
proteins clearly inhibited IFN-mediated antiviral re-
sponse. HCV core or NS4B protein expression alone
showed a weaker effect, whereas other HCV proteins
apparently did not inhibit IFN-mediated antiviral re-
sponse. Pretreatment of core-E1-E2-expressing cells
with low doses of IFN- partially rescued IFN--medi-
ated antiviral response.
RESULTS
Expression of whole HCV polyprotein impairs
IFN-mediated antiviral activity
U-2 OS osteosarcoma cells expressing HCV proteins
in a tetracycline-regulated manner enabled us to study
the effect of HCV gene expression on the antiviral effects
of IFNs. UHCV-11 and UHCV-32 cells expressing the
HCV polyprotein (Moradpour et al., 1998) as well as the
green fluorescent protein (UGFP)-expressing cell lines
were cultured for 40 h in the presence or absence of
tetracycline. The cells were treated with different doses
of IFN- and/or IFN- followed by VSV infection and
analysis of infectious virus production by plaque assay in
Hep-2 cells. HCV gene expression was found to impair
IFN-mediated antiviral activity in UHCV-11 cells but not in
UHCV-32 or UGFP cells. The amount of infectious virus
(PFU/ml) in UHCV-11 cells was approximately 20-fold
higher in the presence of HCV protein expression (tet)
as compared to the same cells in the absence of HCV
gene expression (tet). The greatest difference was
found in the samples pretreated with IFN- 1000 IU/ml
alone or combined with IFN- 100 IU/ml (Fig. 1). It is
noteworthy that relatively high levels of IFN-, up to 100
IU/ml, was required before any antiviral activity was
seen. IFN- alone showed very poor anti-VSV activity.
Western blot analysis was used to estimate the
amount of VSV protein synthesis in IFN-pretreated
UHCV-11 cells (Fig. 2). A reduction comparable to that
seen in the production in infectious VSV (Fig. 1) was also
seen at the level of VSV protein production (Fig. 2). The
reduction in viral protein synthesis appeared to correlate
with the induction of MxB and OAS (especially the p100
form) proteins that occurred only with high IFN doses
were used to stimulate cells (Fig. 2). Some reduction in
IFN--induced expression of MxB or OAS p100 proteins
was seen in HCV protein-expressing cells (tet) (Fig. 2).
To analyze whether HCV protein-expressing U-2 OS
osteosarcoma cell lines produced type I IFNs, we in-
fected them with Sendai virus, which is a strong stimu-
lator of type I IFN production (Pirhonen et al., 1999). No
measurable type I IFN production (sensitivity limit of 3
IU/ml) was seen in Sendai virus infected cells, suggest-
ing that the amount of intrinsic type I IFN production is so
low that it is unlikely to interfere with IFN stimulation
experiments (data not shown).
FIG. 1. IFN-- and IFN--induced antiviral action in cells expressing
the HCV polyprotein. U-2 OS osteosarcoma cells expressing the HCV
polyprotein (UHCV-11 and UHCV-32) or the green fluorescent protein
(UGFP) in a tetracycline-regulated manner were cultured in the ab-
sence or presence of tetracycline for 40 h followed by stimulation with
different doses of IFN-, IFN-, or their combination as indicated in the
figure. After 24 h cells were infected with VSV at an m.o.i. of 1. Cell
culture supernatants were collected at 24 h after infection and the
amount of infectious VSV was analyzed in Hep-2 cells by plaque
titration assay. The results are shown as a relative reduction in VSV
yields. The means (1 SE unit) from three independent experiments
are shown.
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Expression of HCV structural proteins impairs
IFN-mediated antiviral activity
Since the expression of the HCV polyprotein appeared
to interfere with IFN-induced antiviral state (Fig. 1), we
wanted to further investigate which of the HCV proteins
would be responsible for this reduction. Osteosarcoma
cell lines, UCcon-11.17 (low core expression), UCcon-18
(intermediate core), UCcon-39 (very high core, leaky),
UCp7con-9 and Ucp7con-12 (high core-E1-E2-p7), UNS3–
4A-24 (NS3-NS4A), UNS4Bcon-4 (NS4B), UNS5Acon-37.2
(NS5A), UNS5Bcon-5, and UNS5B-8 (NS5B) were cul-
tured in the presence or absence of tetracycline for 40 h
and different doses of IFN- and/or IFN- followed by
infection with VSV for 24 h. The amount of infectious VSV
production to the cell culture supernatants was analyzed
by plaque titration (Fig. 3). IFN-mediated antiviral activity
was found to be weakly impaired in core-expressing
UCcon-39 cell line (very high core expression but leaky)
and very clearly impaired in UCp7con-9 (Core-E1-E2-p7)
(Fig. 3) and UCp7–12 cells (results not shown). The great-
est difference in VSV rescue was seen in the samples
pretreated with IFN- 1000 IU/ml alone or together with
IFN- 100 IU/ml. In UCcon-18 (intermediate core expres-
sion), NS3–4A, or NS5A-expressing cells, no VSV rescue
was seen. Some IFN- resistance, comparable to that
seen in UCcon-39 cells, was also observed in NS4B-
expressing cells. Paradoxically, NS5B expression
seemed to enhance IFN-mediated antiviral effect. NS5B
expression alone had no effect on VSV production,
whereas pretreatment with IFNs (especially with IFN-)
led to decreased VSV production. To rule out the possi-
bility that this is due to an exceptional NS5B-expressing
cell clone, we analyzed another NS5B-expressing cell
line. In UNS5Bcon-5 cells the result was the same as in
UNS5Bcon-8 cell line (Fig. 3). All antiviral experiments
were carried out at least three times and the results were
found to be highly reproducible from one experiment to
another.
To correlate the reduction in infectious VSV production
to viral protein synthesis, Western blot analysis of IFN-
stimulated, VSV-infected UCp7con-9 cells was carried
out (Fig. 4). The expression of VSV G, N, and M proteins
were reduced in IFN-treated HCV protein nonexpressing
cells compared to similarly treated HCV protein-express-
ing cells. Similar to UHCV-11 cells the expression of
FIG. 3. IFN-mediated antiviral response in osteosarcoma cell lines
expressing individual HCV proteins. U-2 OS osteosarcoma cell lines
UCcon-18 (expressing medium levels of core protein), UCcon-39 (very
high core, leaky), UCp7con-9 (high core-E1-E2-p7), UNS3–4A-24 (NS3-
NS4A), UNS4Bcon-4 (NS4B), UNS5Acon-37.2 (NS5A), and UNS5Bcon-8
(NS5B) cells were cultured in the absence or presence of tetracycline
for 40 h followed by stimulation with different doses of IFN-, IFN-, or
their combinations for 24 h as indicated in the figure. The cells were
infected with VSV (m.o.i. of 1) followed by a collection of cell culture
supernatants at 24 h after infection. The amount of infectious VSV
production was analyzed in Hep-2 cells by plaque titration assay. The
means (1 SE unit) from three to four independent experiments are
shown. The results are shown as a relative reduction in VSV yields.
FIG. 2. Western blot analysis of MxB, OAS, and VSV protein produc-
tion in IFN-treated UHCV-11 cells. HCV polyprotein producing UHCV-11
cells were cultured for 40 h in the absence or presence of tetracycline
followed by treatment with different doses of IFNs for 24 h as indicated
in the figure. The cells were infected with VSV (m.o.i. of 1) and har-
vested at 24 h after infection. Cellular proteins (30 g for MxB and OAS
and 10 g for VSV proteins) were separated on 10% SDS–PAGE fol-
lowed by electrotransfer to PVDF (Immobilon) membranes. The filters
were stained with rabbit antibodies against MxB, OAS, and VSV pro-
teins followed by HRP-conjugated secondary antibodies. Protein bands
were visualized by the ECL chemiluminescence system. One represen-
tative experiment is shown.
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structural HCV proteins marginally inhibited IFN-induced
expression of MxB protein, but not that of OAS p100 (Fig.
4). IFN--mediated, dose-dependent upregulation of
MxB protein expression was seen.
Expression levels of HCV core and NS5A proteins in
different cell lines
To correlate the effect of VSV rescue (Fig. 3) with the
expression level of HCV structural proteins, Western blot
analysis for core protein expression was carried out in
different cell lines. UHCV-11, UCcon-18, UCcon-39, and
UCp7con-9 cells were grown in the absence or presence
of tetracycline; cells were harvested and processed for
Western blotting and stained with serum from an HCV-
infected individual. In UHCV-11 and UCcon-18 cells, the
expression level of core protein was relatively low (Fig.
5). In UCcon-39 cells, the core protein expression level in
cells cultured in the absence of tetracycline was very
high but there was also some basal (tet cells) expres-
sion that was comparable to the induced levels seen in
UHCV-11 and UCcon-18 cells. In UCp7con-9 cells, core
protein expression level was high and no basal expres-
sion was seen (Fig. 5). Since the expression of HCV
NS5A protein has been suggested to interfere with the
antiviral effects of IFNs we also analyzed NS5A protein
expression in UHCV11 (expressing the whole HCV ge-
nome) and UNS5Acon32.7 cell lines. NS5A protein ex-
pression was practically equal in both cell lines. The
patient serum used in the assay also stained NS3 protein
in the Western blot (Fig. 5).
IFN- priming partially restores IFN--mediated
antiviral activity in HCV core-E1-E2-p7-expressing
cells
Since the treatment of osteosarcoma cells with a com-
bination of IFN- and IFN- resulted in a higher anti-VSV
activity compared to either IFN alone (Figs. 1 and 3), we
wanted to study whether priming of cells with IFN-
would result in enhanced IFN--mediated antiviral effect.
UCp7con-9 cells were pretreated with IFN- (10 IU/ml for
20 h), tetracycline was removed, and cells were treated
with different doses of IFN- followed by VSV infection
and analysis of virus production. IFN- priming did not
enhance the antiviral activity at low IFN- doses of 10 or
100 IU/ml. However, with higher IFN- doses (1000 to
10,000 IU/ml) IFN- priming could in part overcome HCV
protein-mediated rescue in VSV replication (Fig. 6). With
IFN- doses of 10,000 IU/ml, there was practically no
difference in the antiviral activity between the cells cul-
tured in the presence or absence of tetracycline, sug-
gesting that IFN- priming enhanced IFN--mediated
antiviral response also in the presence HCV gene ex-
pression.
DISCUSSION
HCV infection causes significant morbidity and the
infection remains chronic in most of the infected individ-
uals. Treatment of chronic hepatitis C with IFN- com-
bined with a nucleoside analog ribavirin has shown
promising results (Davis et al., 1998; McHutchison et al.,
1998), although no information of the true eradication of
the virus is yet available. Strong cell-mediated immune
response is thought to be the principal favorable factor in
viral clearance (Cerny and Chisari, 1999; Cooper et al.,
1999; Diepolder et al., 1996). The molecular mechanisms
of IFN resistance of HCV are still under debate (Tan and
Katze, 2001), but it is clear that both viral as well as
FIG. 5. Western blot analysis of HCV core and NS5A protein expres-
sion in HCV protein-expressing osteosarcoma cell lines. UHCV-11,
UCcon-18, UCcon-39, UCp7con-9, and UNS5Acon 32.7 cell lines were
grown in the presence (24 h) or absence of tetracycline for 24 or 48 h.
Cells were collected and cellular proteins (30 g/lane) were separated
on 15% SDS–PAGE followed by electrotransfer to PVDF membranes.
The blots were stained with a serum from an HCV-infected individual
followed by secondary staining with HRP-conjugated anti-human IgG
antibody and autoradiography by the ECL chemiluminescence system.
Viral proteins as indicated in the figure.
FIG. 4. Production of MxB, OAS, and VSV proteins in IFN-treated
UCp7con-9 osteosarcoma cell line. HCV core-E1-E2-p7-expressing
UCp7con-9 cell line was cultured for 24 h in the absence or presence
of tetracycline followed by stimulation with different doses of IFNs as
indicated in the figure. Twenty-four hours after stimulation the cells
were infected with VSV at an m.o.i. of 1 and the cells were harvested at
24 h after infection. Cellular protein was separated on 10% SDS–PAGE
followed by electrotransfer to PVDF membranes. The filters were
stained with rabbit anti-MxB, anti-OAS, or anti-VSV antibodies followed
by secondary staining with HRP-conjugated antibodies. Protein bands
were visualized by the ECL chemiluminescence system. One represen-
tative experiment is shown.
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host-related factors are involved. Unavailability of infec-
tious high-titer HCV stock preparations and inefficiency
of in vitro hepatocyte culture systems has hampered the
research developments. To address the question of
IFN- resistance in more detail, we have used stable cell
lines inducibly expressing different HCV proteins to an-
alyze whether their expression impairs IFN--mediated
antiviral response against VSV.
It has been difficult to establish stable cell lines, es-
pecially hepatocyte-derived ones, that uniformly express
various HCV proteins. In our experiments we used U-2
OS human osteosarcoma-derived cell lines, which allow
HCV protein expression under a control by tetracycline-
sensitive repressor system (Moradpour et al., 1998). We
analyzed IFN-induced antiviral response in cell lines
expressing both the entire HCV polyprotein and the in-
dividual HCV proteins. In agreement with the data by
Francois and co-workers (2000), in UHCV-11 cell line
expressing the whole HCV polyprotein, a clear impair-
ment of IFN-mediated antiviral response was seen. In
the presence of HCV proteins both viral protein synthesis
as well as the production of infectious VSV were en-
hanced in a similar rate (Figs. 1 and 2), suggesting that
HCV may interfere with the ability of IFN- to inhibit the
early steps of VSV replication. In UHCV-11 cell line HCV-
mediated IFN- resistance was not apparently explained
by inhibition of PKR activity, since it was able to phos-
phorylate eIF2 normally (Francois et al., 2000). In West-
ern blot analyses (Fig. 2) we saw some inhibition of
IFN--induced expression of MxB (MxA protein is not
expressed in osteosarcoma cells) and OAS p100 pro-
teins in the presence of HCV gene expression. Accumu-
lating evidence suggests that in human cells HCV gene
expression interferes with IFN--mediated antiviral re-
sponse, but the antiviral molecules inhibited by HCV
have remained unknown. At least there was no direct
correlation to PKR activation or enzymatic activity of p100
OAS (Francois et al., 2000; Podevin et al., 2001). A recent
study carried out in HuH-7 human hepatoma cells by
Frese and co-workers (2001) showed that IFN- inhibited
HCV replicons independent of MxA protein, suggesting
that other IFN--induced antiviral pathways are operat-
ing against HCV.
Experiments carried out in cell lines expressing vari-
ous HCV proteins alone or in different combinations
revealed that the expression of the structural region
(core-E1-E2-p7) clearly impaired IFN--mediated antivi-
ral response. Inhibition in IFN--mediated antiviral activ-
ity occurred at a similar level in cell lines expressing the
whole HCV polyprotein or just the structural region (Figs.
1 and 3), indicating that the expression of the structural
proteins alone may interfere with the IFN system. In cells
expressing the core protein in very high levels (UCcon-
39), there was also some impairment of the antiviral
response. However, this cell line showed some hetero-
geneity in core protein expression as well as some basal
expression of core protein also in the presence of tetra-
cycline (D. Moradpour, personal communication; Fig. 5).
This makes it difficult to make a firm conclusion whether
the core protein alone would be sufficient to block IFN-
-induced anti-VSV activity. HCV core protein has signif-
icant effects at the cellular level. On one hand it can
stimulate various cell signaling pathways such as NF-kB
and AP-1 (Kato et al., 2000) and on the other hand it can
inhibit TNF--mediated signaling and regulate cell
growth and apoptosis (Ray et al., 1998). In mice HCV core
expression impaired their antiviral resistance (Large et
al., 1999), suggesting that the core protein alone may
have immunosuppressive or anti-IFN activities. We also
saw some impairment of the antiviral response in cells
expressing HCV NS4B, which has not been previously
reported. NS4B, which is an integral membrane protein,
was expressed in relatively high levels (Hugle et al.,
2001), which could somehow interfere with the antiviral
actions of IFN-. In cells expressing NS3–4A complex or
NS5A, we could not see any impairment of antiviral
response. The NS5A protein has previously been shown
to be able to, at least partially, inhibit the antiviral activity
FIG. 6. The effect of IFN- pretreatment on IFN--induced antiviral
activity in UCp7con-9 osteosarcoma cell line. HCV core-E1-E2-p7-ex-
pressing UCp7con-9 cell line was grown in the absence or presence of
tetracycline and in the absence or presence of IFN- 10 IU/ml for 20 h.
Thereafter the cells were stimulated with different doses of IFN- (for
24 h) as indicated in the figure followed by infection with VSV at an
m.o.i. of 1. Cell culture supernatants were collected at 24 h after
infection and the amount of infectious VSV was analyzed in Hep-2 cells
by plaque titration assay. The means (1 SE unit) from three indepen-
dent experiments are shown. The results are shown as a relative
reduction in VSV production.
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of interferon against ECMV or VSV infections (Aizaki et
al., 2000; Gale et al., 1999; Polyak et al., 1999; Song et al.,
1999). This resistance was later found to correlate to the
expression level of NS5A as well as to the origin of the
NS5A gene; only the NS5A gene obtained from clinically
IFN- resistant virus showed reduction in antiviral activ-
ity (Podevin et al., 2001). In our experiments the expres-
sion of NS5A protein may have been too low to be able
to interfere with the antiviral actions of IFNs (Fig. 5). Of
interest was the observation that the NS5B protein
seemed to enhance the antiviral actions of IFNs, espe-
cially that of IFN-. Presently, we cannot explain this
phenomenon, but the observation was highly reproduc-
ible and seen in two NS5B-expressing cell clones. An
intriguing possibility is that NS5B protein, being an RNA-
dependent RNA polymerase, acted together with IFN-
induced proteins to interfere with VSV replication.
Since the Jak-STAT pathway (Heim et al., 1999) and the
antiviral activity (Francois et al., 2000; this study) of IFN-
was inhibited by the expression of HCV structural pro-
teins, namely those of core, E1, and E2 (Fig. 3), we
studied whether priming of cells with IFN- would rescue
the antiviral actions of IFN-. The rationale behind this
idea was that IFN- priming enhances STAT1, STAT2, and
p48 gene expression (Lehtonen et al., 1997; Mele´n et al.,
2000) and thus sensitizes the cells to the actions of
IFN-. Indeed, UCp7con-9 cells, which were primed with
low doses of IFN-, showed almost equal IFN--medi-
ated antiviral response irrespective of HCV gene expres-
sion. This rescue was, however, only seen with high
doses of IFN- (Fig. 6). The results suggest that com-
bined treatment with type I and type II IFNs together with
ribavirin could give some benefit over the presently used
HCV treatment regimens. In conclusion, our results indi-
cate that also the structural proteins of HCV (core, E1,
and E2) may contribute to impaired IFN--mediated an-
tiviral response, thus making the question of IFN resis-
tance of HCV a more complex issue.
MATERIALS AND METHODS
Cell culture
The U-2 OS human osteosarcoma-derived, tetracy-
cline-regulated cell lines UHCV-11 and UHCV-32 induc-
ibly expressing the entire HCV polyprotein (Moradpour et
al., 1998), UNS3–4A-24 inducibly expressing the NS3–4A
complex (Wolk et al., 2000), UNS4Bcon-4 inducibly ex-
pressing NS4B (Hugle et al., 2001), UNS5Acon-37.2 in-
ducibly expressing NS5A (Brass et al., 2002) and
UNS5Bcon-5 and UNS5Bcon-8 expressing NS5B (Smidt-
Mende et al., 2001), have been previously described. The
tetracycline-regulated cell lines UCcon-11.17 (low-level
core protein expression), UCcon-18 (medium-level core
protein expression), UCcon-39 (very high-level core pro-
tein expression with some basal expression), and
UCp7con-9 (expression of the entire HCV structural re-
gion) will be described in detail elsewhere (Stutvoet et
al., 2002). In all cell lines, HCV protein expression
reached a steady state at 24–48 h following withdrawal
of tetracycline (Moradpour et al., 1998; Wolk et al., 2000).
The cell lines were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum,
penicillin G 50 U/ml, streptomycin 50 ug/ml, G418 500
ug/ml (Sigma Chemical Comp., St. Louis, MO), puromy-
cin 1 ug/ml (Sigma), and tetracycline 1 ug/ml (Sigma). To
induce HCV protein expression, the cells were washed
once with PBS and once with cell culture medium lacking
tetracycline. To collect the cells, they were briefly
trypsinized at 37°C followed by collection into PBS.
Hep-2 human larynx epidermoid carcinoma cells (ATCC
CCL 23) were used in VSV plaque titrations as described
in detail elsewhere (Cantell et al., 1991).
Interferons
Type I human leukocyte IFN- (6  106 IU/ml; specific
activity of 2  108 IU/mg; Cantell et al., 1981) was kindly
provided by Dr. Kari Cantell at National Public Health
Institute, Helsinki. Human IFN- (1  106 IU/ml; specific
activity of 1.1 107 IU/mg) was obtained from the Finnish
Red Cross Blood Transfusion Service, Helsinki and it
was prepared and purified as described elsewhere (Can-
tell et al., 1986). Interferons were used at concentrations
(IU/ml) indicated in each experiment.
VSV infections and plaque assay
VSV stocks (Indiana strain) were grown in Hep-2 cells
and the stock virus had a titer of 4  106 PFU/ml. Cells
were infected with VSV doses of 1 PFU/cell. To analyze
the production of VSV, plaque assay (Cantell et al., 1991)
was used. Briefly, cell culture supernatants from VSV-
infected cells were used to infect Hep-2 cells for 1 h.
Supernatants were removed followed by addition of aga-
rose. Media was added after solidifying of agarose fol-
lowed by 16 h of incubation. Cells were fixed with for-
malin and stained with crystal violet dye followed by
washing. The plaques were counted and the amount of
infectious virus (PFU/ml) was calculated. Since the
amount of VSV produced varied to some extent from cell
line to another and from one experiment to another, the
results are shown as a relative reduction in virus yields
as compared to virus control.
To analyze possible type I IFN production in U-2 OS
human osteosarcoma cells, they were infected with Sen-
dai virus at 5–10 PFU/cell as previously described (Ke-
skinen et al., 1999). Sendai virus was used since it is a
very good inducer of type I IFNs (Pirhonen et al., 1999).
Culture media from Sendai virus-infected cells were
treated at pH 2 and assayed for the presence of IFN-/
activity in Hep-2 cells by VSV plaque reduction assay
(Cantell et al., 1991).
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Antibodies
In Western blotting the following primary antibodies
were used: rabbit anti-VSV (1:500 dilution; Keskinen et al.,
1999), guinea pig anti-MxB (1:1000; Mele´n et al., 1996),
and rabbit anti-OAS antibodies (1:500; Keskinen et al.,
1999). The sera from HCV-infected patients was kindly
provided by Dr. Maija Lappalainen (Haartman Institute,
University of Helsinki). HRP-conjugated goat anti-rabbit
(1:2000, Dako, Glostrup, Denmark), goat anti-guinea pig
(1:1000, Dako), and HRP-conjugated goat anti-human IgG
(1:1000, Bio-Rad Laboratories, Richmond, CA) or goat
anti-human IgG (Vector) were used as secondary anti-
bodies.
Gel electrophoresis and Western blotting
SDS–PAGE was carried out using the Laemmli buffer
system (Laemmli, 1970). Proteins separated on 10 or 15%
gels were transferred to Immobilon-P (polyvinylidene di-
fluoride, PVDF) membranes (Millipore, Bedford, MA) with
an Isophor electrotransfer apparatus (Hoefer Scientific
Instruments, San Francisco, CA) at 200 mA for 1 h. The
primary and secondary antibody binding was carried out
in PBS containing 5% nonfat milk for 1.5 and 1 h, respec-
tively. After primary and secondary antibody binding, the
filters were washed three times for 10 min. The protein
bands were visualized on Amersham Hyper-Max films by
the ECL chemiluminescence system, as recommended
by the manufacturer (Amersham, Buckinghamshire, U.K.).
Protein concentrations in the samples were determined
with the Bio-Rad protein assay kit.
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